Joe Putnam
Faculty Member
Last active: 3/27/2014

Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.

Roth JA, Atkinson EN, Fossella F, Komaki R, Bernadette Ryan M, Putnam JB, Lee JS, Dhingra H, De Caro L, Chasen M, Hong WK
Lung Cancer. 1998 21 (1): 1-6

PMID: 9792048 · DOI:10.1016/s0169-5002(98)00046-4

Our previously reported randomized study of patients with untreated, potentially resectable clinical stage IIIA non-small-cell lung cancer found that patients treated with perioperative chemotherapy and surgery had a significant increase in median survival compared to patients treated with surgery alone. We have now re-analyzed the results of the study with a median time from random allocation to analysis for all patients of 82 months. The increase in survival conferred by perioperative chemotherapy was maintained during the period of extended observation.

MeSH Terms (12)

Antineoplastic Agents Carcinoma, Non-Small-Cell Lung Chemotherapy, Adjuvant Disease-Free Survival Female Follow-Up Studies Humans Lung Neoplasms Male Middle Aged Survival Analysis Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: